EscharEx bromelain-based enzymatic debridement therapy Updated Nov 5
The next catalyst is the interim sample-size reassessment and enrollment completion of the Phase 3 VALUE trial, expected by end of Q1 2027. A positive interim could de-risk the program and support a sample-size reduction; a negative signal would raise doubts. The topline Phase 3 readout is expected in 2H 2027, which will be the true binary event for the stock. Q3 2026 earnings on November 12, 2026 may provide an enrollment update.
- EscharEx has demonstrated superiority over the market-leading enzymatic debridement product SANTYL ($360M+ annual US sales) in Phase 2 head-to-head data, showing advantages in debridement, granulation tissue promotion, and time to wound closure.
- An independent DSMB reviewed the Phase 3 VALUE trial in September 2026 and recommended continuation without modification, finding no safety concerns.
- Updated US market assessment including pressure ulcers estimates peak annual sales potential of $1.05 billion for EscharEx, targeting a $2.5B+ total addressable market.
- Phase 3 VALUE trial enrollment has been slower than initially anticipated, pushing the interim assessment from mid-2026 to Q1 2027.
- EscharEx is still years from potential approval (Phase 3 readout not expected until 2H 2027 at earliest, then FDA filing and review), meaning no near-term revenue from this asset.
- MediWound's Q2 2026 revenue fell 45.6% year-over-year to $3.1M, and the company remains unprofitable, requiring continued cash burn to fund the EscharEx program.